Arm Forecast, price target & analysts
Arm Target price 2025 - Analyst rating & recommendation
Arm Classifications & Recommendation:
Arm Price Target
| Target Price | $158.10 |
| Price | $142.39 |
| Potential | 11.03% |
| Number of Estimates | 34 |
| 34 Analysts have issued a price target Arm 2026 . The average Arm target price is $158.10. This is 11.03% higher than the current stock price. The highest price target is $220.50 54.86% , the lowest is $77.31 45.71% . | |
| A rating was issued by 42 analysts: 24 Analysts recommend Arm to buy, 15 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Arm stock has an average upside potential 2026 of 11.03% . Most analysts recommend the Arm stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2032
39 Analysts have issued a sales forecast Arm 2026 . The average Arm sales estimate is $4.8b . This is 16.40% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $5.2b 26.77% , the lowest is $4.5b 9.32% .
This results in the following potential growth metrics:
Revenue Estimates
| 2025 | $4.0b | 23.94% |
|---|---|---|
| 2026 | $4.8b | 19.72% |
| 2027 | $5.8b | 21.83% |
| 2028 | $7.1b | 20.74% |
| 2029 | $8.3b | 18.08% |
| 2030 | $9.8b | 17.59% |
| 2031 | $12.1b | 23.34% |
| 2032 | $14.2b | 17.15% |
27 Analysts have issued an Arm EBITDA forecast 2026. The average Arm EBITDA estimate is $2.3b . This is 140.19% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 202.91% , the lowest is $1.8b 87.95% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $916m | 364.97% |
|---|---|---|
| 2026 | $2.3b | 152.51% |
| 2027 | $3.0b | 30.09% |
| 2028 | $3.9b | 30.31% |
| 2029 | $5.1b | 28.79% |
| 2030 | $6.0b | 19.45% |
| 2031 | $7.6b | 25.76% |
EBITDA Margin
| 2025 | 22.86% | 275.16% |
|---|---|---|
| 2026 | 48.22% | 110.94% |
| 2027 | 51.49% | 6.78% |
| 2028 | 55.57% | 7.92% |
| 2029 | 60.61% | 9.07% |
| 2030 | 61.56% | 1.57% |
| 2031 | 62.77% | 1.97% |
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
37 Analysts have issued a Arm forecast for earnings per share. The average Arm EPS is $1.81 . This is 174.24% higher than earnings per share in the financial year 2025. The highest EPS forecast is $2.14 224.24% , the lowest is $1.60 142.42% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2025 | $0.75 | 158.62% |
|---|---|---|
| 2026 | $1.81 | 141.33% |
| 2027 | $2.40 | 32.60% |
| 2028 | $2.95 | 22.92% |
| 2029 | $3.40 | 15.25% |
| 2030 | $3.95 | 16.18% |
| 2031 | $4.64 | 17.47% |
| 2032 | $5.32 | 14.66% |
P/E ratio
| Current | 215.74 | 28.09% |
|---|---|---|
| 2026 | 78.65 | 63.54% |
| 2027 | 59.33 | 24.56% |
| 2028 | 48.28 | 18.62% |
| 2029 | 41.83 | 13.36% |
| 2030 | 36.06 | 13.79% |
| 2031 | 30.71 | 14.84% |
| 2032 | 26.75 | 12.89% |
Based on analysts' sales estimates for 2026, the Arm stock is valued at an EV/Sales of 30.54 and an P/S ratio of 31.14 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 35.55 | 3.46% |
|---|---|---|
| 2026 | 30.54 | 14.10% |
| 2027 | 25.07 | 17.92% |
| 2028 | 20.76 | 17.18% |
| 2029 | 17.58 | 15.31% |
| 2030 | 14.95 | 14.96% |
| 2031 | 12.12 | 18.92% |
| 2032 | 10.35 | 14.64% |
P/S ratio
| Current | 36.25 | 3.37% |
|---|---|---|
| 2026 | 31.14 | 14.09% |
| 2027 | 25.56 | 17.92% |
| 2028 | 21.17 | 17.18% |
| 2029 | 17.93 | 15.31% |
| 2030 | 15.25 | 14.96% |
| 2031 | 12.36 | 18.92% |
| 2032 | 10.55 | 14.64% |
Current Arm Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Seaport Global |
➜
Buy
|
Initiated | Aug 11 2025 |
| UBS |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
| Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
| Raymond James |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
| Rosenblatt |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
| Needham |
Hold
➜
Hold
|
Unchanged | Jul 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Initiated
Seaport Global:
➜
Buy
|
Aug 11 2025 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Jul 31 2025 |
|
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 31 2025 |
|
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Jul 31 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 31 2025 |
|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Jul 31 2025 |
|
Unchanged
Needham:
Hold
➜
Hold
|
Jul 31 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
